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Abstract
Specific cell targeting and efficient intracellular delivery are major hurdles for the widespread 
therapeutic use of nucleic acid technologies, particularly siRNA mediated gene silencing. To 
enable receptor-mediated cell-specific targeting, we designed a synthesis scheme that can be 
generically used to engineer Designed Ankyrin Repeat Protein (DARPin)-siRNA bioconjugates. 
Different linkers, including labile disulfide-, and more stable thiol-maleimide- and triazole- (click 
chemistry) tethers were employed. Crosslinkers were first attached to a 3’-terminal aminohexyl 
chain on the siRNA sense strands. On the protein side thiols of a C-terminal cysteine were used 
as anchoring site for disulfide- and thiol-maleimide conjugate formation, while strain-promoted 
azido-alkyne cycloadditions were carried out at a metabolically introduced N-terminal 
azidohomoalanine. After establishing efficient purification methods, highly pure products were 
obtained. Bioconjugates of EpCAM-targeted DARPins with siRNA directed at the luciferase 
gene were evaluated for cell-specific binding, uptake and gene silencing. As shown by flow 
cytometry and fluorescence microscopy, all constructs retained the highly specific and high-
affinity antigen recognition properties of the native DARPin. As expected, internalization was 
observed only in EpCAM-positive cell lines, and predominantly endolysosomal localization was 
detected. Disulfide linked conjugates showed lower serum stability against cleavage at the linker 
and thus lower internalization into endosomes compared to thiol-maleimide- and triazole-linked 
conjugates, yet induced more pronounced gene silencing. This indicates that the siRNA payload 
needs to be liberated from the protein in the endosome. Our data confirm the promise of 
DARPin-siRNA bioconjugates for tumor targeting, but also identified endosomal retention and 
limited cytosolic escape of the siRNA as the rate-limiting step for more efficient gene silencing.
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Introduction
Therapeutic nucleic acid technologies for gene silencing and eventually gene editing 
generally suffer from insufficient delivery to their target in cytoplasm or nucleus [1]. The 
structural and physicochemical properties of synthetic oligonucleotides, being multiply charged 
hydrophilic oligomers, essentially prevent unassisted cellular uptake into any compartment [2]. 
Two potential solutions are currently being investigated for the delivery issue in preclinical and 
clinical research, namely packaging in liposomes or other nanoparticle formulations [3], or the 
use of bioconjugates as vehicles for receptor-mediated uptake [4]. 
Patisiran, a liposomal formulation of an siRNA against transthyretin (TTR) amyloidosis [5], 
has recently been approved by the FDA and EMA as the first siRNA reaching market 
authorization. The liver is the natural destination organ for particles with the characteristics and 
size of liposomes. A large share of the preclinical and clinical pipelines consists of siRNA and 
antisense conjugates with the GalNAc (N-acetyl galactosamine) ligand [6], shown to be 
efficiently and rapidly internalized into hepatocytes upon binding to the asialoglycoprotein 
receptor [7]. Although this demonstrates the applicability of receptor-mediated endocytosis for 
tumor targeting with nucleic acids, it is questionable whether this concept can be widely used for 
targeting cells other than hepatocytes [1]. Specifically, the asialoglycoprotein receptor has the 
unique characteristics of being expressed in high density on hepatocytes and being internalized 
quickly upon ligand binding with subsequent recycling back to the extracellular membrane [8, 9]. 
Thus, even though GalNAc conjugates are lacking a specific endosomal escape mechanism, 
ostensibly overloading of endosomes suffices to generate adequate cytosolic oligonucleotide 
concentrations for therapeutic gene silencing [10]. Additionally, GalNAc adds no charge and 
very little mass to the oligonucleotide.
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To employ therapeutic receptor-targeting beyond hepatocytes, both highly expressed 
receptors and cognate high-affinity ligands are required. Antibodies remain the gold standard for 
highly specific protein-protein interactions, but because of their structure, low stability, and the 
reliance of posttranslational modifications for correct folding, antibody derivatization and 
bioconjugations are complicated [11]. Designed Ankyrin Repeat Proteins (DARPins) are modular 
protein scaffolds which can be evolved to produce high affinity and binding specificity [12]. 
Having been developed from natural ankyrin proteins, the DARPin consensus framework 
consists of N- and C-terminal repeat domains specifically engineered for high stability, and 
usually three internal repeat domains, which mediate specific protein-protein interactions through 
randomized positions [12]. In recent years, DARPins against an increasing number of different 
antigens have been developed and characterized, and besides direct therapeutic development, 
several biochemical and pharmaceutical applications have been described [12, 13]. DARPins are 
particularly well suited for targeting approaches, because of the ease of derivatization and facile 
site-specific covalent attachment of cargoes [14-16]. For example, unique thiol groups can be 
introduced by a cysteine at any desired position, and strain-promoted azido-alkyne cycloaddition 
(SPAAC, copper-free click chemistry) is afforded by metabolic introduction of an azido-
containing amino acid [17, 18]. With these modifications, controlled site-specific bioconjugation 
of synthetic oligonucleotides is feasible.
We previously reported the generation and use of DARPin fusion proteins for charge-
mediated complexation of siRNA payloads for tumor-targeting [19]. In terms of pharmaceutical 
development, the DARPin bioconjugates have the advantage of being defined single molecules, 
which facilitates reproducibility of the assembly process, quality control, upscaling, and they 
have overall better pharmacokinetic properties to enhance specific delivery to the targeted 
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receptor on cells [20, 21]. Oligonucleotides for intracellular gene silencing and DARPins for 
receptor binding on the cell surface are both modular technologies, and their conjugation is a 
generic process, in principle allowing substituting both the targeted cell surface receptor and the 
gene to be silenced by simply exchanging carrier protein and nucleic acid payload, respectively. 
Here, we describe optimized strategies for the synthesis of DARPin-oligonucleotide 
conjugates with three distinct linker chemistries, their analytical and biochemical 
characterization, and the evaluation of intracellular delivery and gene silencing. To enable in 
vitro characterization under defined conditions, we used a siRNA targeted at luciferase (anti-Luc 
siRNA), and a well-characterized monovalent DARPin with high affinity for the pan-carcinoma 
marker EpCAM [22, 23]. EpCAM is overexpressed in many solid tumors and rapidly internalized 
upon ligand binding [18]. The ability of the various conjugates to inhibit luciferase expression 
and their potential cytotoxicity were examined in EpCAM-positive and negative cell lines.
Materials and Methods
Expression and purification of DARPins
E. coli XL1-Blue (Agilent Technologies, Santa Clara, CA, USA) or B834 (DE3) [17] were 
freshly transformed with a plasmid encoding the anti-EpCAM DARPins Ec4-C, carrying a single 
cysteine at the C-terminus or Ec1 for the incorporation of an N-terminal azidohomoalanine 
(Aha), replacing the initiator Met [22]. For Ec4-C (E. coli XL1-Blue), a single colony was used 
to inoculate LB broth or 2YT medium supplemented with 50 µg/mL ampicillin and 1.0% glucose 
and shaken at 37 °C overnight. The following day, 500 mL of LB broth (Sigma Aldrich, Vienna, 
Austria) or 2YT medium was inoculated to result in an optical density at 600 nm (OD600) of ~0.1 
and the suspension was incubated at 37 °C until an OD600 of 0.4-0.6 was reached. Protein 
  
6
expression was induced by adding isopropyl-β-D-thiogalactopyranoside (IPTG, final 
concentration 0.5 mM; Thermo Fisher, Waltham, USA) and the culture was shaken at 37 °C for 
4 h. 
For the expression of Aha-modified Ec1 in E. coli B834 (DE3), Pre-M9 medium (SelenoMet 
basal medium (Molecular Dimensions) with 40 mg/L L-methionine, 5% (v/v) glucose-free 
nutrient mix (Molecular Dimensions), 50 mg/L ampicillin, and 1% (w/v) glucose), was 
inoculated with a single colony of transformed bacteria. The next day, 500 mL Pre-M9 medium 
was inoculated to an OD600 of ~0.1 and the bacterial suspension was shaken at 37° C until an 
OD600 of 1.0-1.2 was reached. The culture was subsequently centrifuged (Eppendorf, Vienna, 
Austria) at 4 °C for 15 min and washed thoroughly three times by resuspending the pellet in ice-
cold PBS followed by centrifugation. The remaining pellet was transferred into M9 medium 
(SelenoMet basal medium with 40 mg/L L-azidohomoalanine (H-Dab(N3)·HCl, Bapeks, Riga, 
Latvia), 5% (v/v) nutrient mix, 50 mg/L ampicillin, and 0.4% (w/v) glycerol. The bacterial 
culture was agitated for 15 min at 30 °C, then expression was induced with 1 mM IPTG followed 
by incubation at 37°C for 4 h. Thereafter, bacteria were collected by centrifugation at 4,000 rpm 
for 20 min. The pellets were dried and stored at -80 °C. 
After thawing, each pellet was resuspended in 30 ml of 20 mM HEPES, 500 mM NaCl, 25 
mM imidazole, pH 8.0 and a spatula tip of lysozyme was added and the solution was incubated 
for 30 min. The solution was thoroughly sonicated with cooling between sonication cycles until 
the cells were disrupted. The lysate was centrifuged for 30 min at 16,000 x g and the supernatant 
was loaded into PD-10 columns packed with Ni-NTA resin (Qiagen, Hildesheim, 1 ml per 10-30 
mg protein), which had been equilibrated with 20 mM HEPES, 500 mM NaCl, 25 mM imidazole, 
pH 8.0. After supernatant loading, the column was washed with 10 column volumes 20 mM 
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HEPES, 500 mM NaCl, 25 mM imidazole, pH 8.0 and the protein eluted using 20 mM HEPES, 
500 mM NaCl, 300 mM imidazole, pH 8.0. During the elution, fractions of 0.5-1 ml were 
collected. Protein containing fractions were pooled and dialyzed against PBS. For Ec4-C, all 
buffers contained 5 mM DTT. 
siRNA
All fluorescently labelled and unlabelled siRNAs were synthesized at GlaxoSmithKline 
(GSK, Stevenage, UK). For all bioconjugates, a siRNA complementary to luciferase mRNA 
(anti-Luc siRNA) was used (sense strand, CUUACGCUGAGUACUUCGA-PS-dT-PS-dT with a 
3’-aminohexyl linker, antisense strand, UCGAAGUACUCAGCGUAAG-dT-PS-dT; underlined 
nucleotides are 2’-O-methylated, PS indicates phosphorothioate bonds). 
Attachment of crosslinkers to 3’-aminohexyl sense strands
The sense strand of 3’ aminohexyl-modified anti-Luc siRNA was dissolved in nuclease free 
water (Sartorius arium® pro, Göttingen, Germany) to give a 1 mM solution. For generation of the 
disulfide-linked bioconjugate, the succinimidyl 3-(2-pyridyldithio)propionate (SPDP, Thermo 
Scientific, Waltham, USA) crosslinker was dissolved in anhydrous dimethyl sulfoxide (DMSO; 
Sigma Aldrich, Vienna, Austria) to a 20 mM solution. A 5-fold molar excess of SPDP crosslinker 
(500 nmol) was added to the solution of the sense strand (100 nmol) and the reaction was 
buffered to a final concentration of 47 mM sodium phosphate buffer (Gibco, Life Technologies, 
Carlsbad, USA), adjusted to pH 8.5. The solution was mixed gently for 1 hour at 25 °C. The 
excess of SPDP crosslinker was removed by precipitation of the SPDP-crosslinked anti-Luc 
siRNA with 2-propanol and centrifugation at 13,000 x g for 10 min at 4 °C. The pellet was 
washed three times with 75% ice-cold ethanol and finally dissolved in nuclease-free water.
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For the preparation of thiol-maleimide-linked bioconjugate, sulfosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (Sulfo-SMCC; Thermo Fisher, Waltham, USA) 
crosslinker was dissolved in nuclease free water to a 10 mM solution. A 50-fold molar excess of 
Sulfo-SMCC (5 µmol) was added to the sense strand of 3’-aminohexyl-anti-Luc siRNA 
(100 nmol) in 47 mM sodium phosphate buffer, adjusted to pH 7.7 and mixed at 25 °C for 3 h. 
For the synthesis of the dibenzocyclooctyne (DBCO)-crosslinked siRNA sense strand, a 
10 mM solution of DBCO-NHS ester (Sigma Aldrich, Vienna, Austria) was prepared in DMSO. 
A 10-fold molar excess (1 µmol) was added to the sense strand of 3’-aminohexyl-modified anti-
Luc siRNA (100 nmol) and the reaction was buffered with 47 mM sodium phosphate buffer, pH 
7.4. The reaction was shaken in a thermoincubator at 25 °C for 2 h. To remove the excess of 
linkers, thiol-maleimide- and DBCO-derivatized anti-Luc siRNA were purified by size exclusion 
chromatography on an ÄKTA Pure chromatography system equipped with a Superdex 75 10/300 
GL column (GE Healthcare, Vienna, Austria) with elution with 47 mM sodium phosphate buffer, 
pH 7.4 at a flow rate of 0.5 mL/min. Fractions containing derivatized sense strand of siRNA were 
collected, pooled and concentrated to a 100 to 200 µM solution with 3 kDa Amicon centrifugal 
filters (Merck Millipore, Darmstadt, Germany). 
Reversed Phase High performance liquid chromatography (HPLC)
All oligonucleotide-crosslinker reactions were monitored by RP-HPLC measurements 
(Shimadzu, Korneuburg, Austria) on a reversed phase column for oligonucleotide analysis 
(Clarity 5 µ RP18 250 x 4.60 mm, Phenomenex, Torrance, USA). For all runs, a 60 min linear 
gradient of 8-44% acetonitrile in triethylammonium acetate (TEAA) buffer in nuclease-free 
water, adjusted to pH 7.0 was performed at a flow rate of 1 mL/min. Before RP-HPLC 
measurement, 25 mM dithiothreitol (DTT) was added to SPDP-crosslinked siRNA sample for 
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disulfide cleavage. All siRNA samples were diluted to a 50 µM solution with TEAA buffer for 
measurements. 
Electrospray ionization mass spectrometry (ESI-MS)
Samples for ESI-MS measurements were purified as published [24]. To this end, 30 µL of a 
25 µM siRNA sample were mixed in 15 µL 7.5 M ammonium acetate solution and left at room 
temperature for 1 hour. After addition of 115 µL of ethanol, the samples were precipitated 
overnight at -80° C. The samples were centrifuged for 30 min at 12,000 x g and 0 °C to collect 
the oligonucleotide. After washing with 100 µL ice-cold 75% ethanol and centrifugation for 
20 min at 12,000 x g and 0 °C, the pellet was air-dried and dissolved in 50 µL nuclease-free 
water. For MS analyses, the samples were diluted to a 10 µM solution with 10 mM ammonium 
acetate in RNase-free water. Since direct ESI-MS measurement of intact pyridyldithiol-
oligonucleotide resulted in mulitple peaks, the disulfide bond was cleaved by DTT at a final 
concentration of 10 mM directly before ESI-MS measurement, which better maintained integrity. 
Analyses were performed on an electrospray-quadrupole time-of-flight mass spectrometer 
(Bruker maXis HD, Bremen, Germany). Calibration was done with ES-TOF Tuning Mix (Sigma 
Aldrich, Vienna, Austria) and the samples were measured in negative mode.
Reduction of C-terminal cysteine-modified DARPin Ec4
Cysteine-modified DARPin Ec4-C was reduced with 25 mM DTT in 20 mM Tris, 200 mM 
NaCl, pH 8.0 at 37 °C for 30 min. Excess DTT was removed by size exclusion chromatography 
in a 15 mL polypropylene column with Sephadex G50 (GE Healthcare, Vienna, Austria) and 
gravity flow elution with nuclease free water. Protein-containing fractions were identified by 
nanophotometric measurements with a NanoDrop ND-1000 instrument (Peqlab Biotechnologie 
  
10
GmbH, Erlangen, Germany) and pooled. The volume was reduced to reach a concentration 
between 1.0 and 2.0 mg/mL. 
Synthesis of DARPin-based siRNA conjugates
For the disulfide-linked bioconjugate, a 2-fold molar excess of freshly reduced Ec4-C 
(38 nmol, 2.0 mg/mL) was added to the SPDP-sense strand (19 nmol). A guanidinium 
hydrochloride (GdnHCl) buffer (4.5 M GdnHCl, 20 mM Tris, pH 8.0) or a phosphate buffer (13.5 
mM KCl, 9 mM KH2PO4, 685 mM NaCl, 50 mM Na2HPO4, 4.5 mM CaCl2, 2.5 mM MgCl2-
6H2O, pH 7.4) was added and the reaction was incubated at 25 °C for 24 h. For the thiol-
maleimide-linked conjugate, a 2-fold molar excess of monomeric Ec4-C (64 nmol) was dissolved 
in phosphate buffer, added to the thiol-maleimide-crosslinked sense strand (32 nmol) and the 
reaction was incubated at 25 °C for 24 h. The DBCO-linked conjugate was generated by adding a 
2-fold molar excess of Aha-Ec1 (60 nmol, 10.5 mg/mL) buffered in phosphate buffer, pH 7.4 to 
the DBCO-modified sense strand (30 nmol) and the reaction was incubated at 25 °C for 3 h. 
Purification of bioconjugates
To remove unreacted oligonucleotide, Ni-NTA agarose was added to the reaction mixtures 
and incubated under shaking at room temperature for 30 min. The slurry was transferred into a 
spin column (Pierce, Waltham, USA) and washed with 1x DPBS until no siRNA was detected by 
nanophotometric measurements (260 nm absorption maximum). Unreacted Ec4-C and conjugate 
were eluted with 250 mM imidazole in nuclease-free water and the respective fractions were 
pooled.
For separation of unreacted protein, oligonucleotide-based affinity chromatography was used. 
A synthetic 3’ biotinylated 2’-desoxy-oligonucleotide (AGCATCAGTCGCGTAAG) with partial 
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complementarity to the siRNA strand was immobilized on streptavidin sepharose (GE 
Healthcare, Vienna, Austria). The conjugate was applied to the immobilized DNA and unreacted 
protein was removed by washing with ice-cold high salt buffer (2x DPBS). The conjugate was 
eluted in low-salt buffer (0.4 mM KCl, 0.2 mM KH2PO4, 20.0 mM NaCl and 1.2 mM Na2HPO4, 
pH 7.4) at 35 °C. 
Duplex formation 
Equimolar amounts of DARPin-single strand siRNA conjugate and the corresponding 
antisense strand either with or without Alexa Fluor 568 label at a 3’-aminohexyl linker were 
mixed in nuclease-free water. For verifying complete hybridization, an aliquot of the mixture (20 
pmol) with labelled antisense was incubated at room temperature for 10 min or at 60 °C for 5 
min. After incubation, samples were mixed with DNA loading dye (0.01% bromophenol blue, 
20% sucrose) and analyzed on a 20 % native acrylamide gel (7.5 mL 40% 29:1 
acrylamide:bisacrylamide, 1.5 mL 10x TBE buffer, 6.0 mL water, 7.5 µL tetramethylethylene 
diamine, 75 µL 10 % ammonium persulfate). The gel was run in 1x TBE buffer at 100 V for 
90 min, digitalized in a Ettan Dige Imager (GE Healthcare, Vienna, Austria) and analyzed with 
ImageQuant™ TL software.
Stability test and agarose gel electrophoresis
Disulfide-, thiol-maleimide- and DBCO-linked conjugates were incubated in DMEM with 
10% FBS at 37 °C for 0 h, 1 h, 3 h, 24 h and 48 h (Thermomixer, Eppendorf). Samples were 
analyzed on a 2% agarose gel with a final concentration of 0.5 µg/mL ethidium bromide. The gel 
was scanned in a ChemiDocTM XRS gel imaging system (Bio-Rad, Vienna Austria,) and 
analyzed using the QuantityOne Software (Bio-Rad, Vienna, Austria). 
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Cell culture
HeLa, MDA-MB-468, and MCF-7 cell lines were obtained from the European Collection of 
Authenticated Cell Cultures (ECACC). Cells were cultivated in Dulbecco’s Modified Eagle 
Medium (DMEM) + GlutaMaxTM (Gibco, Carlsbad, USA) supplemented with 10% FBS (Gibcoat 
37 °C and 5% CO2. For passaging cells were washed with pre-warmed PBS, trypsinized with 
TrypLE™ Express (Gibco), and resuspended in pre-warmed medium.
EpCAM-specific binding activity of bioconjugates
Antigen-specific binding activity was tested by flow cytometry on EpCAM-positive MDA-
MB-468 cells and EpCAM-negative HeLa cells. After trypsinization and resuspension in DMEM 
(10% FBS), cells were counted in a Thoma chamber. Cells were washed with 3 mL PBS and 
centrifuged for 10 min at 4 °C and 200 x g (Eppendorf, Vienna, Austria). The supernatant was 
removed and the cells were resuspended in the appropriate volume of FACS buffer (PBS with 
1% FBS) to give a density of 1.2 x 106 cells/mL. The indicated amount of bioconjugate (330 or 
1330 nM), Ec4-C or Aha-Ec1 was added to 1.8 x 105 MDA-MB-468 or HeLa cells and the 
mixture was incubated for 1 h on ice. Afterwards cells were washed twice with 1 mL FACS 
buffer, centrifuged for 10 min at 4 °C/100 x g and the supernatant was removed. Cells were 
resuspended in 200 µl FACS buffer containing 2 µl anti-penta·His Alexa 488 mouse IgG1 
(Qiagen, Hilden, Germany) and incubated on ice for 1 h. After washing twice, the cells were 
resuspended in 500 µl ice-cold FACS buffer, cooled on ice and immediately analyzed by flow 
cytometry. The same procedure except incubation with the anti-penta His antibody was carried 
out with Alexa Fluor 568 labelled conjugates at 330 and 1330 nM.
On a BD FACSCaliburTM flow cytometer (BD Bioscience, San Jose, USA), 104 cells per 
sample were analyzed with the filter settings for the respective fluorophores. Results were 
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quantified by BD CellQuest™ (BD Bioscience, San Jose, USA) and FlowJo (FlowJo LLC, 
Ashland, USA) software. 
EpCAM-specific uptake studies
EpCAM-specific uptake of siRNA containing an Alexa Fluor 568 labeled antisense strand, 
was investigated by flow cytometry and confocal microscopy on EpCAM-positive MDA-MB-
468 cells and EpCAM-negative HeLa cells. For flow cytometry, cells were seeded in a 24-well 
plate at a density of 105 cells in 200 µL. Cells were cultured under standard conditions for 24 h. 
The medium was removed, and the bioconjugates (330 and 1330 nM) as well as controls diluted 
in DMEM with 10% FBS were added and cells were incubated for 24 h. The medium was 
removed, cells were washed twice with 500 µL FACS buffer, and trypsinized. The cells were 
resuspended in 500 µL FACS buffer, cooled on ice and immediately analyzed as described above. 
Cell specific uptake and intracellular trafficking of bioconjugates were monitored on MCF-7 
and HeLa cells by confocal microscopy. Per 35 mm imaging dish (MatTek, Ashland, MA, USA) 
2 x 105 cells (21,000 cells/cm2) HeLa and 3 x 105 cells per dish (32,000 cells/cm2) MCF-7 were 
seeded and incubated for 48 h under tissue culture conditions. For uptake experiments in MCF-7 
and HeLa, cells were incubated with 200 µL of bioconjugate (400 nM) in DMEM/10% FBS for 
6 h before washing in imaging medium (phenol-red-free DMEM/20 mM HEPES (Gibco) and 
10% FBS) and imaged by confocal microscopy. For analyzing binding and uptake, MCF-7 cells 
were pre-chilled on ice for 15 mins before incubating with ice cold 200 µL of bioconjugate 
(400 nM) in DMEM/10% FBS for 1 h. Cells were subsequently washed in ice-cold imaging 
medium and imaged by confocal microscopy. After imaging, cells were returned to 37 °C/5% 
CO2 for 2 h before re-imaging by confocal microscopy. To assess lysosomal localization, MCF-7 
cells were incubated with 0.1 mg/mL Alexa Fluor 488 dextran conjugate (Life Technologies) for 
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2 h in medium containing 10% FBS. Cells were subsequently washed and reincubated in fresh 
serum containing medium overnight to allow the dextran probe to reach a terminal endocytic 
compartment. Cells were subsequently incubated with 400 nM of bioconjugates in medium 
containing FBS (final volume 200 µL) for 6 h before washing and imaging by confocal 
microscopy in imaging medium containing 5 µg/mL Hoechst 33342.
Confocal microscopy was performed on a Leica SP5 LCSM using 60x 1.4NA objective, 
488 nm Argon and 543 nm HeNe lasers with a raster size of 1024 x 1024 giving a pixel size of 
96.1 nm2 at a depth of 8 bits. 
Luciferase reporter assay
We used MCF-7 and HeLa cells transduced with a lentiviral vector encoding a PGK-EGFP-
Luc cassette as described previously [25], the mRNA of which is complementary to the antisense 
strand of the anti-Luc siRNA. To ensure that the conjugates are able to induce gene silencing 
after reaching the cytosol, Lipofectamine RNAiMAX was used for transfecting DARPin-
conjugates as well as the unconjugated siRNA. The indicated amounts of bioconjugates or siRNA 
diluted in 20 µL Opti-MEM (Gibco, Carlsbad, USA) were transferred into corresponding wells of 
a white 96-well plate (Greiner Bio-One, Kremsmünster, Austria) and 2.5 x 104 MCF-7 or 2.0 x 
104 HeLa cells in 80 µL per well were added in DMEM with 10% FBS. For some experiments, 
cells were co-incubated with 1 µM conjugates and 62.5 µM chloroquine. After 48 h incubation, 
the medium was removed and cells were washed with 100 µL pre-warmed PBS. Passive lysis 
buffer (20 µL; Promega, Mannheim, Germany) was added to each well and cells were lysed for 
30 min at RT with gentle shaking. Luciferin substrate (100 µL per well; 3.0 mg/mL luciferin in 
20 mM glycylglycine, pH 7.8, 1 mM MgCl2, 1 mM EDTA, 3.3 mM DTT, 0.5 mM ATP, 0.3 mM 
coenzyme A) was added via the plate reader’s injector and luminescence signals were measured 
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immediately (Tecan infinite M200Pro, Tecan, Grödig, Austria). The relative gene knockdown 
was calculated relative to untreated cells. Statistical significance was calculated by one-way 
ANOVA with Bonferroni post-hoc correction, and p-values <0.05 were considered significant.
Viability assay
The EZ4U proliferation assay (Biomedica, Austria, Vienna) was used for determination of 
cell viability after incubation of MCF-7 and HeLa cells with bioconjugates. Bioconjugates 
(20 µL) were transferred into a 96-well plate at a concentration of 5, 3 and 1 µM, and 2 x 104 
MCF-7 or 1.5 x 104 HeLa cells in 80 µL per well were added in DMEM/10% FBS. Cells were 
incubated for 24 h at 37 °C and 5% CO2. After 24 h incubation, the medium was discarded and 
EZ4U substrate, prepared according to the manufacturer’s instructions, was added to each well. 
The absorbance was measured at 470 nm in a plate reader (Tecan infinite M200Pro) at 15 
minutes intervals until the absorbance of untreated samples had reached 2.0. Additionally, the 
absorbance at 650 nm was measured as reference. The relative viability was calculated 
normalized to untreated cells. Statistical significance was calculated by one-way ANOVA with 
Bonferroni post-hoc correction, and p-values <0.05 were considered significant.
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Results
Synthesis, purification and analysis of pyridyldithiol-, Sulfo-SMCC- or DBCO-crosslinked 
oligonucleotides 
In order to synthesize bioconjugates linked with a disulfide, thiol-maleimide or triazole bond 
between DARPin and siRNA, the siRNA sense strand was tethered to the respective bifunctional 
crosslinkers, which were in turn linked to an engineered protein thiol. Accordingly, 3’ amino-
modified anti-luciferase siRNA sense strands were reacted with N-succinimidyl 3-(2-
pyridyldithio)propionate (SPDP), sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-
carboxylate (Sulfo-SMCC) and dibenzocyclooctyne (DBCO) crosslinkers, respectively 
(Figure 1). All reactions were carried out in amine-free aqueous buffer solutions with separately 
optimized pH values of 7.4 or 7.7 with a 10- to 50-fold molar excess of crosslinkers, achieving 
high yields under these conditions. For removing unreacted crosslinkers and other side products, 
thiol-maleimide-crosslinked sense siRNA was purified by size exclusion chromatography (SEC) 
on a Sephadex column. Partial cleavage of the disulfide of pyridyldithiol-oligonucleotide and 
limited solubility of DBCO-oligonucleotide in aqueous buffers hampered yields after SEC, and 
thus the respectively modified oligonucleotides were instead purified by precipitation from a 
mixture of sodium acetate and isopropanol. 
HPLC analyses demonstrated that the reaction of anti-Luc siRNA sense strand (rt = 15.6 min) 
with the three crosslinkers yielded a nearly complete conversion to pyridyldithiol- (rt = 
27.5 min), thiol-maleimide- (rt = 24.7 min) or DBCO-crosslinked (rt = 33.3 min) sense strand in 
1 to 3 h reaction time (Figure 2). In addition, the removal of side products by size exclusion 
chromatography or precipitation was confirmed, and the large peak of the NHS hydrolysis 
product at rt = 3 min that was detected in reaction mixtures was absent after purification. 
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Figure 1: Conjugation scheme. The N-hydroxy succinimide ester derivatives of SPDP, Sulfo-
SMCC or DBCO linkers were tethered to 3’ aminoalkyl siRNA sense strands. After purification, 
  
18
the DARPins (with unique L-azidohomoalanine or cysteine for site-specific conjugation) were 
attached to yield bioconjugates of single stranded oligonucleotides with the proteins. siRNA 
duplexes were then generated by adding an equimolar amount of the antisense strand and 
incubation at room temperature.
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Figure 2: RP-HPLC analyses of amine-modified anti-Luc siRNA (A) and purified 
pyridyldithiol- (B), thiol-maleimide- (C) and DBCO-crosslinked (D) siRNA sense strands. 
Separations were achieved on a reversed phase C-18 column. A linear gradient of 8-44% 
acetonitrile in triethylammonium acetate (TEAA) buffer during 60 min was applied at a flow rate 
of 1 mL/min. 
The yields of purified siRNAs with linkers were 44% (thiol-maleimide after SEC), 63 % 
(DBCO after precipitation, 36 % after SEC), and 84% (pyridyldithiol after precipitation), 
indicating variable loss of product depending mainly on the purification method. ESI-MS 
measurements are consistent with the masses of all crosslinked siRNA sense strands (Table 1 and 
Supplementary Figure 2). Since attempts with the intact pyridyldithiol-oligonucleotide showed 
predominantly degradation products, the disulfide bond was intentionally reductively cleaved 
prior to MS to obtain cleaner spectra. Partial substitution of one sulfur of the phosphorothioate 
backbone by oxygen either during synthesis or MS ionization [26] resulted in a minor byproduct 
of pyridyldithiol siRNA. 
Oligonucleotide Mass calculated Mass found
pyridyldithiol (reduced) 7073.07 Da 7073.04 Da, 7057.06 Da
thiol-maleimide 7207.85 Da 7208.10 Da
DBCO 7272.16 Da 7272.12 Da
Table 1. ESI-MS analysis of SPDP-, thiol-maleimide- and DBCO-modified siRNA sense strands
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Synthesis of DARPin-based siRNA bioconjugates
For generating siRNA-bioconjugates, we used the EpCAM-specific DARPins Ec4 and Ec1, 
which differ only by few amino acids and have largely the same binding characteristics, including 
binding to the identical epitope [22]. Detailed characterization of binding has been described 
previously [17, 18, 22]. All conjugation reactions (Figure 1) were individually optimized through 
reaction monitoring by gel electrophoresis and HPLC. 
Initially, reactions were carried out in native buffers with equimolar ratios of proteins and 
oligonucleotides. Reaction monitoring showed conversion to a product with a molecular weight 
corresponding to the expected conjugate. However, even after reaction times of over 24 h, both 
oligonucleotide and protein educts were still present, and in the case of cysteine-modified 
DARPin, dimerization occurred with increased reaction times, which prevents full protein 
conversion. In order to facilitate purification, we then conducted reactions with a two-fold excess 
of protein, which allowed full consumption of the oligonucleotide in maleimide-thiol and 
SPAAC reactions within 24 h, indicated by a shift of the peak in HPLC analyses without 
detectable oligonucleotide educt (Figure 3 E and F). However, the preparation of the disulfide 
conjugate by reaction of the pyridyldithiol oligonucleotide failed to result in complete conversion 
of the oligonucleotide, and with increasing reaction time, a number of side products were formed 
(data not shown). An increase of the formation of the desired disulfide bioconjugate was achieved 
by using a denaturing buffer with 4.5 M GdnHCl within a reaction time of 24 h. Since 
denaturation of DARPins requires high concentrations of up to 5 M of denaturing reagents and 
high temperatures, these conditions did not lead to complete denaturation of DARPin [13, 27]. 
The incomplete reaction under native conditions was attributed to the lability of the pyridyldithiol 
function, which also complicated MS analysis (see above). The increase in yield by GndHCl 
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supplementation might be caused by better access to the protein coupling site or by the high salt 
concentration for reduced charge expulsion between the reactants, thus favoring the conjugation 
reaction before linker cleavage. 
Figure 3 Reaction monitoring of bioconjugate syntheses by gel electrophoresis (A-C) and 
HPLC (E and F), and duplex association monitored by gel shift assay (D). A-C: SDS 
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polyacrylamide gels were loaded with protein samples, reaction mixtures, and purified 
conjugates, and stained with Coomassie blue. Disulfide-linked DARPin-oligonucleotide 
conjugate (26.1 kDa) after 24 h reaction at rt (A), thiol-maleimide-linked DARPin-
oligonucleotide conjugate (25.9 kDa) after 3 h at rt (B), and triazole-linked DARPin-
oligonucleotide conjugate (25.6 kDa) after 3 h at rt (C), all with unreacted DARPin (18.9 kDa 
for A and B and 18.3 kDa for C) and purified bioconjugate as indicated. The DARPin Ec4-C 
dimerizes under the reaction conditions, which limits the conjugation yield. D: Hybridization of 
Alexa Fluor 568 tagged antisense strand to DARPin-sense strand conjugates and analysis on a 
native polyacrylamide gel with fluorescence detection. The tagged antisense strand was added to 
the corresponding sense strand or to the disulfide DARPin-oligonucleotide conjugate, incubated 
at rt for 10 min or at 60 °C for 5 min. As controls, an siRNA duplex, the antisense single strand 
and free Alexa Fluor 568 dye were analyzed. The absence of a band of free antisense strands in 
lanes 2 and 3 proves complete hybridization to the DARPin-sense strand conjugate. E, F: RP-
HPLC traces of thiol-maleimide DARPin-oligonucleotide conjugate reaction mixture (E) and 
triazole DARPin-oligonucleotide conjugate reaction mixture (F) showing conjugate formation 
and absence of oligonucleotide educts; unreacted proteins failed to elute during the gradient run. 
Analytical HPLCs were conducted on a reversed phase C-18 column with a linear gradient of 
8-44% acetonitrile in triethylammonium acetate (TEAA) buffer during 60 min at a flow rate of 
1 mL/min. 
As expected, gel electrophoresis analyses showed that disulfide-linked and thiol-maleimide-
linked bioconjugate samples were separated in three bands each representing unreacted 
monomeric Ec4-C at 18 kDa, dimeric Ec4-C (36 kDa) and the siRNA-Ec4 conjugate at 25 kDa. 
Triazole-linked conjugate separation resulted in a band of unreacted Aha-Ec1 at 18 kDa and a 
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band representing the DARPin-siRNA conjugate at 25 kDa (Figure 3). Unlike for the triazole 
conjugate, attempts to purify the disulfide- and thiol-maleimide linked conjugates by semi-
preparative HPLC resulted in low product recovery, and thus we resorted to a two-step-affinity 
purification strategy for removing excess educts. First, unreacted oligonucleotides were removed 
by capturing His-tag containing compounds on a Ni-NTA resin. In order to remove unreacted 
DARPins, we developed an oligo-based affinity chromatography. While unconjugated Ec4-C was 
eluted in high-salt buffer, the conjugate was effectively bound to an immobilized oligonucleotide 
with partial complementarity (7 nucleotides) to the siRNA sense strand. The conjugate was then 
eluted in low-salt buffer. On the other hand, DBCO-linked DARPin-oligonucleotide conjugate 
was successfully purified by semi-preparative RP-HPLC. After purification, all bioconjugates 
showed high compound homogeneity, with a single band at 25 kDa, and no remnants of 
uncoupled proteins detected on SDS-polyacrylamide gels (Figure 3 A-C). 
Conjugation yields were determined by measuring absorption at 260 nm, the absorbance 
maximum of oligonucleotides. The final yields after purification were 30% (disulfide), 35% 
(thiol-maleimide) and 47% (triazole) for conjugation reactions starting with 30-40 nmol 
oligonucleotide. As only minor amounts of oligonucleotide starting material was found in 
reaction mixtures (Figure 3), the majority of product loss occurred during purification of the 
relatively small amounts of bioconjugates.
Formation of double-stranded DARPin-siRNA bioconjugates and degradation in serum 
After successful covalent attachment of the sense strand to the targeting protein, the siRNA 
was completed by hybridization of the antisense strand to the conjugates. Complete duplex 
formation was verified on a native polyacrylamide gel (Figure 3D). Due to the increased 
molecular weight and less negative charge-to-mass ratio, the double-stranded conjugate migrated 
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more slowly than double-stranded anti-Luc siRNA, the single strand or the unattached dye. A 
single incubation step of 10 min at room temperature was sufficient for complete duplex 
formation based on Watson-Crick base pairing, indicating that the attachment of the DARPin did 
not influence the hybridization capability of the nucleic acids strands (Figure 3D), and a heating-
cooling cycle is not required for efficient duplex formation. 
Figure 4: Agarose gel electrophoretic analyses show different time-dependent cleavage of 
conjugates at the linker, releasing double stranded siRNA, in 10 % FBS in DMEM at 37 °C. 
The stability of DARPin-siRNA conjugates was evaluated in cell culture medium 
supplemented with 10% FBS at 37 °C. Degradation of the disulfide conjugate was observed 
within 24 h, with a band appearing at the size of full-length siRNA. This indicates at least partial 
reductive cleavage at the linker site through glutathione present in FBS (Figure 4). Thiol-
maleimide- and triazole- conjugates exhibit higher stability and only minor degradation occurred 
during 48 h. A slow reverse reaction of the thiol-maleimide bonds under physiological conditions 
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has been described before [28]. Being stabilized by chemical modifications, the siRNA itself was 
not readily cleaved by serum nucleases.
EpCAM-specific binding activity
Specific binding activities of the bioconjugates to EpCAM-positive and EpCAM-negative 
cell lines were analyzed by flow cytometry after incubation at 4°C (Figure 5). To ensure both cell 
association and bioconjugate integrity, we evaluated binding by two fluorescent reporters: a 
protein-specific penta-His antibody and a labelled siRNA antisense strand. As shown in Figure 5, 
on MDA-MB-468 cells all conjugates showed strong cell association. For disulfide and thiol-
maleimide conjugates, binding signals detected by the penta-His antibody were identical to those 
of the unmodified DARPin. Cellular association of the triazole conjugate was considerably lower. 
However, no significant change in signal was encountered between the conjugates when cell 
association was detected through a fluorescently labelled siRNA cargo. Therefore, the reduced 
signal of the His-tag antibody is obviously caused by an interference of the antibody-protein 
binding instead of weaker binding of the conjugate to cells. In contrast to oligonucleotide 
attachment via the C-terminal thiol, tethering of the cargo to the N-terminal azido group adjacent 
to the His-tag compromises accessibility for the antibody. On HeLa cells, a weak shift of the 
fluorescence intensity was detected for Ec4, and to a lower extent of the conjugates. This was 
attributed to the high target affinity of Ec4, which in this relatively high concentration is able to 
bind also to cells with minimal EpCAM expression, although we cannot formally rule out a small 
amount of unspecific binding. Flow cytometry analysis with an anti-EpCAM antibody showed a 
very slight association to HeLa cells (Supplementary Figure 1), in line with available 
transcriptomic data [29, 30].
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Figure 5: Binding of conjugates to EpCAM-positive MDA-MB-468 cells and EpCAM-low HeLa 
cells. Conjugates and controls were incubated with cells at 4 °C for 1 h. The fluorescence signal 
for evaluation of EpCAM-specific protein binding was provided by the fluorescent secondary 
antibody anti-penta-His Alexa 488 mouse IgG1, which binds to the N-terminal His-tag of the 
DARPin, but is sterically blocked by the N-terminally conjugated triazole conjugate. For 
verification of the integrity of the conjugates and an orthogonal quantitation, the antisense strand 
of anti-Luc siRNA was labelled with Alexa Fluor 568 and detected in flow cytometry. 
After incubation of EpCAM-positive MDA-MB-468 cells with bioconjugates and free siRNA in 
indicated concentrations for 24 h at 37° C and for providing internalization and after thorough 
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washing to remove surface bound compounds, the fluorescence signals were quantified by flow 
cytometry.
EpCAM-specific uptake studies
Flow cytometry analysis of bioconjugates and siRNA uptake in MDA-MB-468 cells showed 
a concentration-dependent cellular binding and/or uptake of disulfide-linked and thiol-maleimide-
linked bioconjugates (Figure 5). However, the more stable maleimide-linked bioconjugate was 
associated with cells to a higher extent than the disulfide-linked DARPin-siRNA bioconjugate.
For a detailed analysis of uptake and internalization and to determine the requirement of 
EpCAM, we incubated the bioconjugates with EpCAM positive MCF-7 [31] and EpCAM-low 
control HeLa cells [29 , 30] for 6 h in complete medium (Figure 6A). A comparison between 
EpCAM-positive cell lines showed that MDA-MB-468 and MCF-7 cells had similar abundance 
of EpCAM (Supplementary Information) and thus showed similar conjugate binding, but MCF-7 
resulted in slightly superior cellular uptake. Therefore, we investigated intracellular trafficking 
and gene silencing in MCF-7 cells. From these incubations, both thiol-maleimide and disulfide 
conjugates were shown to label the plasma membrane in MCF-7 cells to different extents with 
fluorescence, also visible in a juxtanuclear compartment. In contrast, cell-associated fluorescence 
was much lower in HeLa cells compared to MCF-7 with no overall intra- or extracellular 
localization visible. It is of interest to note that extracellular membrane localization of the 
disulfide linked conjugates was reduced, likely explained by the lower stability, and perhaps 
reducing components at the cell surface [32].
To determine a requirement for energy in the internalization of the EpCAM targeting 
bioconjugates, MCF-7 cells were incubated with thiol-maleimide and disulfide conjugates on ice 
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for 1 h (Figure 6B). Both conjugates bound equally to the cells with no internalization or 
juxtanuclear labelling visible, indicating that the differences in intensity between the two 
bioconjugates in Figure 6A is not due to differential binding to the cell surface. Cells were 
subsequently warmed to 37 °C for 2 h and reanalyzed by confocal microscopy to show that 
internalization is an active endocytic process. Again, we detected a reduction in cell-associated 
fluorescence with the disulfide conjugate but not with the thiol-maleimide conjugate. This re-
affirms our hypothesis that the disulfide link is being cleaved at the cell surface before the 
bioconjugate is fully internalized, and reducing functions at the cell surface have been described 
[32].
Internalized fluorescence was shown to localize to a juxtanuclear compartment and we 
decided to test whether the fluorescently tagged siRNA trafficked to lysosomes. Lysosomes were 
labelled in MCF-7 cells with dextran using a pulse-chase technique we have reported in detail 
previously [33]. Pre-incubation with dextran results in accumulation in LAMP1 positive 
lysosomes after endosomal trafficking through Rab7 positive late endosomes [34], and this 
protocols specifically stains lysosomes. The bioconjugates were incubated with the cells for 6 h 
(Figure 6 C). As seen previously, the disulfide-linked bioconjugate has far lower cell-associated 
fluorescence than the thiol-maleimide conjugate, however, the vast majority of the fluorescence 
appears to be localized to lysosomes, with very few structures not colocalizing with the dextran 
in this organelle. Again, the thiol-maleimide linked bioconjugate showed both internalized and 
plasma membrane associated fluorescence. While there are differences in the extent of 
internalized fluorescence within the cell population, the fluorescence signal predominately 
localizes to the lysosome, indicating that when either conjugate is finally endocytosed, the 
ultimate location of the fluorescently labeled siRNA is this organelle.
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Figure 6: Cellular uptake properties of EpCAM binding bioconjugates labelled with Alexa Fluor 
568 antisense strands examined by fluorescence microscopy. A, Binding and uptake of 400 nM 
bioconjugate in EpCAM positive (MCF-7) and EpCAM negative (HeLa) cells after 6 h 
continuous incubation. B, Cell surface binding of 400 nM bioconjugates incubated with MCF-7 
on ice for 1 h and after a subsequent 2 h incubation at 37°. C. Dextran-488 (green) was pulsed 
for 2 h and chased overnight to label lysosomes, MCF-7 were incubated with 400 nM 
bioconjugate (red) for 6 h and imaged on the confocal microscope. Arrows indicate siRNA co-
localized with lysosome, arrowheads indicate siRNA-alone. Images represent single sections, 
scale bars = 10 µm.
Luciferase reporter assay
Reduction of luciferase gene expression was determined on respective cell lines stably 
expressing luciferase. Initial characterization was afforded using transient transfection of the 
targeted luciferase gene. However, due to varying transfection efficiency, considerable variation 
and poor reproducibility was encountered (data not shown), and therefore we used cell lines with 
stable expression of luciferase by lentiviral transduction. Since the triazole conjugates failed to 
show target downregulation in the transiently transfected cell lines (data not shown), we only 
evaluated the disulfide and thiol-maleimide conjugates in the stable luciferase expressing cell 
lines. To examine gene silencing after receptor-mediated internalization, disulfide- and thiol-
maleimide-conjugates were applied without transfection reagent in full cell culture medium to 
EpCAM-positive MCF-7 and EpCAM-negative HeLa cells. 
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Figure 7: Gene silencing and cell viability of EpCAM-positive MCF-7 cells and control 
EpCAM-low HeLa cells after treatment with bioconjugates. A: Luciferase reporter cell lines were 
used for evaluation of gene silencing of firefly luciferase targeted siRNA-conjugates. Cells were 
incubated with conjugates (in the presence or absence of 62.5 µM chloroquine) in cell culture 
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medium containing 10% FBS for 48 h. Cells were lysed and luminescence signals were evaluated 
after addition of luciferin. Data are means ± s.d., n = 3, *: p<0.05. B, Cell viability after 24 h 
incubation with bioconjugates measured by a formazan assay. Data are mean s± s.d., n=3, *: 
p<0.05.
As shown in Figure 7, the luminescence reporter assay analysis of disulfide-linked 
bioconjugates indicated a significant decrease of the luminescence signal to 62%, whereas the 
more stable thiol-maleimide-linked bioconjugate showed only a minor gene silencing effect in 
MCF-7 cells (Figure 7A). In contrast, no decrease of luminescence signal was detectable for 
either disulfide- or thiol-maleimide-linked conjugate in HeLa cells (Figure 7A). These results 
confirm the EpCAM-specificity, but also highlight a rather low silencing activity. Lipoplex-
mediated transfection of conjugates proved that they are intrinsically capable of inducing gene 
silencing to the same extent as free siRNA, and a scrambled siRNA failed to induce silencing. 
Addition of chloroquine, an endosomolytic agent, improved gene silencing activity approx. 2-
fold for the disulfide-conjugate, and enables silencing with the thiol-maleimide conjugate. Thus, 
a lack of effective cytosolic concentration, caused by uptake into endosomal compartments and 
poor endosomal escape, is obviously responsible for the moderate gene silencing effects. The fact 
that the cleavable disulfide-linked conjugate shows higher silencing activity indicates that the 
released oligonucleotide itself, butnot the intact conjugate is delivered to the cytoplasm, albeit at 
low levels.
Viability assay
A possible impact on cell viability and proliferation was investigated by a formazan-based 
assay on MCF-7 and HeLa cells after incubation with the bioconjugates. For all conjugates, no 
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significant signal reduction was found at any concentration (Figure 7B) for MCF-7. A slight 
reduction of HeLa cell viability was detected for the triazole-conjugate at high concentrations.
Discussion
Sufficient intracellular delivery still constitutes a major hurdle in the use of therapeutic 
oligonucleotides for medical applications, in particular when targeting diseased tissues other than 
the liver [1, 10, 21]. Receptor-specific uptake appears to be an attractive strategy for increasing 
intracellular delivery of antisense and siRNA oligonucleotides. For effective binding and 
internalization, appropriate ligands with high receptor affinity and selectivity are essential [4]. 
Designed Ankyrin Repeat Proteins (DARPins) bind with similar affinity and selectivity as 
antibodies, but they are devoid of posttranslational modifications, have high chemical and 
thermal stability, can easily be produced in high yields in bacterial expression systems, and allow 
facile functionalization for site-specific derivatization [12, 35-37]. Overall, the structural and 
functional properties of DARPins make them attractive options as carriers for receptor-targeted 
delivery within oligonucleotide bioconjugates. Previously described fusion proteins for charge 
complexation of the siRNA cargo resulted in receptor-specific in vitro silencing, but they 
aggregate into supramolecular assemblies with a particle size of around 200 nm [19], which 
might lead to liver targeting, independent of the receptor. The biodistribution of nanoparticles is 
determined to a large extent by their nanoscale characteristics, such as the EPR effect, and 
molecular targeting has limited influence [38]. Thus, we hypothesized that molecular DARPin-
siRNA bioconjugates have superior targeting properties. We decided to attach the carrier protein 
covalently to the sense strand, in order to minimize a potential negative influence on recruitment 
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by RISC, for which the antisense strand is essential. While the sense strand was chemically 
modified by 2’-O-Me pyrimidines and two phosphorothioate linkages to increase stability against 
enzymatic degradation, the antisense strand was largely unmodified except for a distinct 
phosphorothioate at the 3’-end, to avoid negative effects on gene silencing efficacy. After 
successful synthesis and purification of single stranded conjugates, the complete siRNA-DARPin 
conjugates were produced by strand hybridization of the antisense complement, proceeding even 
without the need for heating.
We identified specific binding only on EpCAM-positive cells for all bioconjugates, with 
negligible binding on HeLa cells. Although generally regarded as EpCAM-negative, HeLa 
expresses a low basal amount of this protein (Supplementary Information and [29, 30]), and the 
high affinity of DARPins Ec1 and Ec4 for EpCAM resulted in detectable binding to this cell line. 
Comparison of bioconjugates with the parent Ec1 and Ec4 in flow cytometric analyses with a 
secondary anti-penta·His antibody showed that the DARPins retained their binding activity and 
specificity after being tethered to siRNA. 
Concentration-dependent assessment of internalization indicated a specific, EpCAM-
mediated process. No internalization was observed at 4 °C showing that an active endocytic 
process is involved, also evidenced by the punctuate pattern. These results are in good 
accordance with data of effective internalization of EpCAM-specific DARPins by receptor-
mediated endocytosis [22]. Additionally, co-staining with a lysosomal marker indicated that all 
internalised bioconjugates were predominantly localized in lysosomes after 6 hrs. It should be 
noted that even after several hours, substantial staining of the plasma membrane was observed 
suggesting a slow endocytic turnover of this receptor by this method (Figure 6). No significant 
diffuse stain was noticed.
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The functional examination of productive cellular uptake, i.e. cytosolic escape, by assessing 
gene silencing of the luciferase reporter gene resulted in moderate activity of the disulfide 
conjugate, while thiol-maleimide and also triazole conjugates failed to induce silencing to the 
level observed with the commercial transfection reagent. Similar to other targeting approaches, 
insufficient endosomal escape is apparently responsible for the moderate silencing activities [10]. 
Direct transfection of the conjugates showed strong silencing and this underlines the lack of 
localization to the cytosol as a limiting step. Endosomal destabilization with chloroquine 
significantly improved gene silencing (Figure 7) to 60 % and 30 % reduction of luminescence for 
the disulfide and thiol-maleimide conjugate, respectively. This constitutes an at least two-fold 
increase in silencing efficacy and further corroborates endosomal entrapment subsequent to 
receptor-mediated uptake as the hurdle for efficient gene silencing. In vitro, silencing was 
moderate and occurred after incubating cells with 3 µM concentrations, which would be difficult 
to achieve in tumor tissue in vivo. DARPin-mediated binding to the cell surface receptor is 
typically already saturated at a ten-fold lower concentration. Therefore, increasing productive 
uptake into the cytosol after receptor binding would be crucial. Considering necessary and 
achievable tissue concentrations, recently published data [39] indicated that concentrations of 
GalNAc siRNA conjugates in rodent livers of about 20-200 nM result in strong silencing, with 
only a small percentage of that loaded to the RISC. Approximately 2 µM siRNA conjugate 
concentrations were measured in the liver after dosing 2.5 mg/kg. Although tissue concentrations 
in other organs are usually lower, bioconjugate concentrations in the high nanomolar range thus 
appear to be achievable.
Linker stability is an important aspect for any carrier-cargo conjugate. On the one hand, 
linkers need to be sufficiently stable in circulation to enable intact delivery to the extracellular 
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receptor [40]. For an antibody-drug conjugate linker stability was found to correlate positively 
with the pharmacologic effect [40]. Conversely, the cargo may need to be removed from the 
carrier molecule to be effective. In the case of oligonucleotides, few data on the influence of 
linker stability exists, and it is not sufficiently clear if the carrier needs to be cleaved from the 
siRNA duplex, whether the whole conjugate might find its way into the cytosol, or if the 
antisense strand can eventually be recruited directly to the RISC complex. The different results 
generated with different linker chemistries, including a disulfide designed to be cleaved in 
endosomal and lysosomal environments with high glutathione concentrations [41], highlights the 
importance of the carrier-cargo binding. Indeed, the disulfide-linked compound had better 
silencing efficacy than the more stable conjugates. While cleavage was observed in serum-
supplemented solutions (containing glutathione [42]), lower overall cellular internalization, yet 
significantly stronger gene silencing was induced with the labile-linked conjugate. This indicates 
that separation, most probably in endosomes, of carrier and cargo is decisive for achieving 
productive cytosolic delivery, indicating that only the oligonucleotide duplex is translocated to 
the cytoplasm at some level, but not the whole conjugate. Improved linkages with higher 
extracellular stability, but rapid cleavage within endosomes might improve silencing potencies of 
siRNA conjugates.
While cell recognition and endosomal uptake of the DARPin siRNA conjugates are highly 
specific, intracellular trafficking, in particular endosomal escape leaves space for improvement. 
Besides linkers optimized for serum stability but endosomal cleavage, strategies for further 
optimization include incorporation of a biocompatible endosomal destabilization reagent either as 
an adjuvant or by covalent attachment [43, 44]. Gene silencing effects of bioconjugates could 
also be improved by selecting receptor systems with better uptake kinetics, particularly faster 
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internalization rates. The hepatocytic asialoglycoprotein protein receptor, which is targeted by 
successful GalNAc conjugates for siRNA and antisense, is characterized by a rapid recycling 
time of around 15 min allowing high uptake rates of GalNAc conjugates [10, 45]. Thus, DARPin-
siRNA bioconjugates targeting receptors with higher uptake rates and recycling would lead to a 
faster recycling time and consecutively, higher siRNA concentrations could reach the cytosol. 
However, precise uptake and intracellular trafficking routes depend on a multitude of factors, 
many of which are still incompletely understood [46, 47].
Conclusion
The bioconjugates developed herein serve as prototype and can be easily adapted for different 
targets at the receptor level (by selecting DARPins for other antigens), and for different genes to 
be silenced (by using respective siRNA sequences). Our data highlights high in vitro cell-type 
specificity and the beneficial effects of cleavable linkers, while suggesting endosomal escape to 
be the bottleneck for the development of more efficient targeted siRNA therapeutics. In contrast 
to other approaches, the bioconjugates and the synthetic procedures presented herein are highly 
modular, as both targeting protein and effector molecules are homogenous in their structural and 
biophysical properties, independent of their target. The synthetic methodology and purification 
and characterization procedures can likewise be adopted for other DARPin-siRNA conjugates 
and represents a versatile system for receptor-targeted siRNA delivery. 
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